FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

							J 00	, 51 1110				0. 20 40							
Name and Address of Reporting Person* Schenkein David P						2. Issuer Name and Ticker or Trading Symbol AGIOS PHARMACEUTICALS INC [AGIO								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
		_ []]									O#i (i titl-			Other (
(Last) (First) (Middle)							of Earl	est Trans	saction (Mont	h/Dav/Vear)		-	X	below) below) Chief Executive Officer				
C/O AGIOS PHARMACEUTICALS, INC. 88 SIDNEY STREET							3. Date of Earliest Transaction (Month/Day/Year) 05/30/2018									nief Exe	cutive	Officer	
(0, 1)		- 4. 1	4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line)							
(Street) CAMBRIDGE MA 02139													X						
- V2100							Form filed by More than One Reporting												
(City) (State) (Zip)						Person													
		Tak	le I - N	on-Deri	vativ	e Se	curit	ies Ac	quire	d, Di	isposed o	f, or Be	nefici	ally	Owned				
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/						/Year) Exec		A. Deemed secution Date, any lonth/Day/Year)		ction Instr.		ies Acquired (A) or Of (D) (Instr. 3, 4 and			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)		Form:	Direct Indirect E	. Nature of ndirect eneficial ownership
									8) Code	v	Amount	(A) or (D) Price					,,,,,,		Instr. 4)
Common stock 05/30/2						018			M ⁽¹⁾		5,962	A	\$0.30	25	5,9	962		D	
Common stock 05/30/20)18			M ⁽¹⁾		16,193	A	\$0.30	25	22,1	155		D	
Common stock 05/30/20)18		M ⁽¹⁾		23,471	A	\$0.46	75	45,6	45,626		D		
Common stock 05/30/20)18		S ⁽²⁾		45,626	D	\$90.0	7 ⁽³⁾	C)		D		
Common stock														271,	271,772			See ootnote ⁽⁴⁾	
Common stock															79,082				See cootnote ⁽⁵⁾
			Table II								posed of, converti				wned		,		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deer Execution if any (Month/I	ned	4. Transa Code (8)	ection	5. Number tion of		6. Date Exerc Expiration Do (Month/Day/)		cisable and	7. Title and Amo of Securities Underlying Derivative Secu (Instr. 3 and 4)		nt 8 D S	. Price of lerivative ecurity nstr. 5)	9. Numbo derivativ Securitie Beneficia Owned Followin Reported Transact (Instr. 4)	e es ally g	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4	Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercis	able	Expiration Date	Title	Amour or Number of Shares	er					
Stock option (right to buy)	\$0.3025	05/30/2018			M ⁽¹⁾			5,962	(6)		08/12/2019	Common stock	5,96	2	\$0.00	0		D	
Stock option (right to buy)	\$0.3025	05/30/2018			M ⁽¹⁾			16,193	(7)		08/12/2019	Common stock	16,19)3	\$0.00	0		D	
Stock option (right to buy)	\$0.4675	05/30/2018			M ⁽¹⁾			23,471	(8)		03/01/2021	Common stock	23,47	1	\$0.00	12,89	92	D	

Explanation of Responses:

- 1. This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- 2. This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- 3. The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of \$90.00 to \$90.63. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- 4. Shares held by David P. Schenkein 2004 Revocable Trust, of which the reporting person is trustee and beneficiary.
- 5. Shares held by Amy P. Schenkein 2004 Revocable Trust, of which the reporting person's spouse is trustee and beneficiary.
- 6. This option was granted on August 13, 2009. The shares underlying this option vested as to 25% of the shares on August 1, 2010, and the remaining 75% vested in 36 equal monthly installments thereafter.
- 7. This option was granted on August 13, 2009. The shares underlying this option vested as to 50% upon the achievement of a performance milestone, as determined by the issuer's Board of Directors on June 3, $2010, and the \ remaining \ 50\% \ of \ the \ underlying \ shares \ vested \ in \ equal \ monthly \ installments \ through \ June \ 3, \ 2013.$
- 8. This option was granted on March 2, 2011. The shares underlying this option vested as to 25% of the shares on the date of grant and as to 25% of the shares upon the achievement of a performance milestone on July 19, 2013. The remaining 50% of the shares underlying the option vested in equal monthly installments through July 19, 2015.

Remarks:

in Fact for David Schenkein

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.